Forgot your password?

Forgot your username?

database > company
CSL Behring
P.O. Box 61501, 1020 First Avenue
King of Prussia, PA 19406 USA
phone:610-878-4000
fax:610-878-4009
Symbol
Exchange
Founded
Employees
www.cslbehring.com
Research Sector
Summary Description
Developing biotherapies for people with rare and serious diseases worldwide.
Management
Peter Turner, President; Alan Anderson, Vice President, Western Europe; Greg Boss, Senior Vice President and CSL Group General Counsel; Wally Casey, Senior Vice President and General Manager, Kankakee Plant; Karen Etchberger, Senior Vice President, Global Quality; Randy Furby, Senior Vice President and General Manager, CSL Plasma; Dennis Jackman, Senior Vice President, Public Affairs; Uwe E. Jocham, Senior Vice President and General Manager, CSL Behring AG; Robert Lefebvre, Vice President and General Manager, U.S. Commercial Operations; Roland Martin, Senior Vice President and General Manager, CSL Behring GmbH, Marburg; Gordon Naylor, Executive Vice President, Plasma, Supply Chain and Information Systems; Paul R. Perreault, Executive Vice President, Worldwide Commercial Operations; Kathy Quay, Senior Vice President, Human Resources; Val Romberg, Senior Vice President, Research and Development; Sergio Scrofani, Senior Vice President, Business Development; Dr. Ingolf Sieper, Vice President and General Manager, Commercial Operations, Central Europe; Markus Staempfli, Vice President and General Manager, Intercontinental Commercial Operations; Kiyoaki Yamabe, Vice President and General Manager, CSL Behring K.K.
Ownership
Financials Mkt Cap :
* numbers in thousands
 
Keywords
plasma, congenital fibrinogen deficiency, hereditary angiodema, transplants

Comment | Printable Version | Modify profile |
Updated: Dec. 02, 2009

Description
CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market biotherapies to treat rare, often life-threatening conditions. Our customers rely on our therapies to help them live better and, in many cases, longer lives. CSL Behring’s commitment to changing the lives of people with serious and rare conditions shows in everything we do. Whether manufacturing and marketing safe and effective products or researching and developing innovative biotherapies, our first and foremost focus is always on fulfilling our customers' needs.